Mount Sinai

Mount Sinai has announced a collaborative research agreement to evaluate a novel liquid radioembolic agent for treating brain tumors. The therapy would deliver radiation directly to tumor tissue in liquid form, an approach being explored for cancers that are difficult to treat surgically. Details on the partner institution, trial design and timeline have not yet been released, and clinical results remain pending.